Cargando…

Comparative study of clinicopathological characteristics and prognosis between combined and pure small cell lung cancer (SCLC) after surgical resection

BACKGROUND: Histologically, SCLC are classified as pure (P‐SCLC) and combined subtypes (C‐SCLC). Currently, few studies compare the clinicopathological characteristics and explore the treatment strategies applied to them. METHODS: Between July 2005 and April 2016, the clinical records of 297 postope...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Yiying, Yang, Lin, Liu, Li, Wei, Jiacong, Teng, Fei, Zhang, Jinyao, Zhu, Yixiang, Xing, Puyuan, Li, Junling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529571/ https://www.ncbi.nlm.nih.gov/pubmed/32779385 http://dx.doi.org/10.1111/1759-7714.13591

Ejemplares similares

Clinicopathological features and prognostic implications of ASCL1 expression in surgically resected small cell lung cancer
por: Wei, Jiacong, et al.
Publicado: (2020)

ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China
por: Hu, Chunfang, et al.
Publicado: (2021)

Clinicopathological Difference and Survival Impact of Patients with c-SCLC and SCLC
por: Zhang, Chenyue, et al.
Publicado: (2021)

Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD)
por: Xie, Tongji, et al.
Publicado: (2020)

Clinical significance of ALDH1A1 expression and its association with E-cadherin and N-cadherin in resected large cell neuroendocrine carcinoma
por: Zhang, Jinyao, et al.
Publicado: (2022)

ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer
por: Sun, Dantong, et al.
Publicado: (2021)

Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
por: Mu, Yuxin, et al.
Publicado: (2020)

Prognostic significance of YAP1 expression and its association with neuroendocrine markers in resected pulmonary large cell neuroendocrine carcinoma (LCNEC)
por: Sun, Xujie, et al.
Publicado: (2022)

Nab-paclitaxel in combination with Bevacizumab in patients with non-squamous non-small cell lung cancer after failure of at least one prior systemic regimen
por: Hao, Xuezhi, et al.
Publicado: (2020)

Heterogeneity in intracranial relapses after complete resection of lung adenocarcinoma: Distinct features of brain‐only relapse versus synchronous extracranial relapse
por: Xu, Fei, et al.
Publicado: (2023)

Clinicopathological characteristics and prognosis of resected cases of carcinoid tumors of the lung
por: Yang, Zhi, et al.
Publicado: (2016)

Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in EGFR-Mutant Lung Adenocarcinoma
por: Li, Teng, et al.
Publicado: (2021)

Different clinical characteristics and survival between surgically resected pure and combined small cell lung cancer
por: Li, Yujing, et al.
Publicado: (2022)

Clinicopathologic and molecular characteristics of 44 patients with pure secretory breast carcinoma
por: Li, Lijuan, et al.
Publicado: (2019)

Apatinib as maintenance therapy following standard first‐line chemotherapy in extensive disease small cell lung cancer: A phase II single‐arm trial
por: Teng, Fei, et al.
Publicado: (2022)

Is transformed small cell lung cancer (SCLC) different from de novo SCLC?
por: Park, Cheol-Kyu, et al.
Publicado: (2019)

The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China
por: Xing, Puyuan, et al.
Publicado: (2017)

Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression
por: Xu, Ziyi, et al.
Publicado: (2022)

Analysis of the clinicopathological characteristics, genetic phenotypes, and prognostic of pure mucinous adenocarcinoma
por: Chen, Zhencong, et al.
Publicado: (2019)

Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis
por: Xie, Tongji, et al.
Publicado: (2021)

Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: a network meta-analysis
por: Xu, Ziyi, et al.
Publicado: (2022)

Front-line therapy for brain metastases and non-brain metastases in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a network meta-analysis
por: Zhu, Yixiang, et al.
Publicado: (2023)

Sonic Hedgehog in SCLC
por: Laukkanen, Mikko O., et al.
Publicado: (2015)

Pathology and Classification of SCLC
por: Raso, Maria Gabriela, et al.
Publicado: (2021)

Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast
por: Jang, Yunjeong, et al.
Publicado: (2020)

Disease monitoring of epidermal growth factor receptor (EGFR)‐mutated non‐small‐cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA
por: Li, Yan, et al.
Publicado: (2022)

Efficacy and safety profile of combining programmed cell death‐1 (PD‐1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non‐small cell lung cancer (NSCLC)
por: Xu, Ziyi, et al.
Publicado: (2021)

Tumor and host characteristics of small cell lung cancer (SCLC) in U.S. community oncology practice
por: Richards, Donald, et al.
Publicado: (2015)

Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC)
por: Ding, Xiao-Long, et al.
Publicado: (2022)

Evaluation of calculating carboplatin dosage in carboplatin–pemetrexed therapy as the first‐line therapy for Chinese patients with advanced lung adenocarcinoma
por: Zhu, Yixiang, et al.
Publicado: (2018)

A 15-Gene-Based Risk Signature for Predicting Overall Survival in SCLC Patients Who Have Undergone Surgical Resection
por: Atay, Sevcan
Publicado: (2023)

Analysis of Clinicopathological Characteristics and Prognosis of Carcinosarcoma of the Breast
por: Tian, Yao, et al.
Publicado: (2022)

Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity‐matched analysis in a cohort of 147 recurrences
por: Xu, Fei, et al.
Publicado: (2022)

Chemotherapy- and Immune-Related Gene Panel in Prognosis Prediction and Immune Microenvironment of SCLC
por: Chen, Meng-Yu, et al.
Publicado: (2022)

Clinicopathological characteristics and treatment outcome of resectable gastric cancer patients with small para-aortic lymph node
por: Yao, Zhendan, et al.
Publicado: (2023)

Diagnosis, clinicopathological characteristics and prognosis of pulmonary mucinous adenocarcinoma
por: Sun, Fei, et al.
Publicado: (2018)

Comparison of Clinicopathological Features and Prognosis between ALK Rearrangements and EGFR Mutations in Surgically Resected Early-stage Lung Adenocarcinoma
por: Li, Pupu, et al.
Publicado: (2019)

What Are the Biomarkers for Immunotherapy in SCLC?
por: Longo, Vito, et al.
Publicado: (2021)

Prophylactic cranial irradiation in SCLC
por: Suwinski, Rafal
Publicado: (2021)

Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis
por: Xing, Puyuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_86o48g2ocuqsnrifq5c93mg8im